|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
ES2466715T3
(es)
|
1999-06-25 |
2014-06-11 |
Immunogen, Inc. |
Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6333410B1
(en)
*
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
EP1992643A3
(fr)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Compositions et procédés pour le traitement et le diagnostic d'une tumeur
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
EP2143438B1
(fr)
|
2001-09-18 |
2011-07-13 |
Genentech, Inc. |
Compositions et méthodes pour le diagnostic et le traitement de tumeurs
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
US20050276812A1
(en)
*
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
|
EP1627069A4
(fr)
*
|
2002-08-08 |
2010-06-02 |
Glaxosmithkline Llc |
Procedes d'isolation et de purification d'ansamitocines
|
|
US7432088B2
(en)
*
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
|
EP1633784B1
(fr)
|
2003-05-09 |
2011-07-13 |
Diadexus, Inc. |
Compositions d'anticorps anti-ovr110, et leur procede d'utilisation
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
CR20170291A
(es)
|
2003-05-20 |
2017-07-27 |
Immunogen Inc |
Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
|
|
ES2424353T3
(es)
|
2003-07-08 |
2013-10-01 |
Genentech, Inc. |
Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
|
|
EP1664115A2
(fr)
*
|
2003-08-01 |
2006-06-07 |
Genentech, Inc. |
Sequences de polypeptide anticorps cdr avec une diversite restreinte
|
|
NZ596984A
(en)
|
2003-11-17 |
2013-10-25 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
PT1771474E
(pt)
|
2004-07-20 |
2010-05-03 |
Genentech Inc |
Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
|
|
RU2405041C2
(ru)
|
2004-07-26 |
2010-11-27 |
Дженентек, Инк. |
Способы и композиции для модуляции активации фактора роста гепатоцитов
|
|
AU2004224925C1
(en)
*
|
2004-08-30 |
2011-07-21 |
Biotest Ag |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
HUE058817T2
(hu)
*
|
2004-09-03 |
2022-09-28 |
Genentech Inc |
Humanizált anti-béta7 antagonisták és alkalmazásaik
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US7964195B2
(en)
|
2005-01-07 |
2011-06-21 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
ES2503719T3
(es)
*
|
2005-02-11 |
2014-10-07 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
|
CA2619577A1
(fr)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Disruptions et compositions geniques et procedes associes
|
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
|
EP1957531B1
(fr)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
|
|
US20090293137A1
(en)
|
2005-11-21 |
2009-11-26 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
EP1973951A2
(fr)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Polypeptides de liaison avec des sequences de diversite limitees
|
|
EP1957540B1
(fr)
*
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Polypeptides de liaison et leurs utilisations
|
|
WO2007126439A2
(fr)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions et méthodes de traitement de maladies et troubles associés é la signalisation de la cytokine
|
|
KR101538521B1
(ko)
|
2005-12-15 |
2015-07-22 |
제넨테크, 인크. |
폴리유비퀴틴 표적화를 위한 방법 및 조성물
|
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
|
KR101459160B1
(ko)
|
2006-01-20 |
2014-11-19 |
제넨테크, 인크. |
항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
|
|
WO2007114979A2
(fr)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Nouvelles disruption géniques, compositions et procédés associés
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
|
CL2007001536A1
(es)
|
2006-05-30 |
2008-01-25 |
Genentech Inc |
Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
|
|
NZ574215A
(en)
|
2006-07-18 |
2012-07-27 |
Sanofi Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
|
WO2008033782A2
(fr)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Procédés et compositions pour le diagnostic et le traitement du cancer
|
|
EP1914242A1
(fr)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
|
EP2061814B1
(fr)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Anticorps et immunoconjugues, et leurs utilisations
|
|
EP2121743B1
(fr)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
|
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Ｒｏｂｏ４ 항체 및 그의 용도
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
TWI417099B
(zh)
|
2007-03-23 |
2013-12-01 |
Neuraxon Inc |
具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
|
|
EP2132312B1
(fr)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructions et bibliothèques comprenant des séquences de chaînes légères de substitution d'anticorps
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
ES2672769T3
(es)
|
2007-08-29 |
2018-06-18 |
Sanofi |
Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
|
|
EP2050764A1
(fr)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Nouveau format d'anticorps bispécifique polyvalent
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
CN104059143A
(zh)
*
|
2007-11-12 |
2014-09-24 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
BRPI0821447A2
(pt)
*
|
2007-12-26 |
2015-06-16 |
Biotest Ag |
Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
|
|
DK2242772T3
(en)
*
|
2007-12-26 |
2015-01-05 |
Biotest Ag |
Immunoconjugates that targets CD138, and uses thereof
|
|
CN101945892B
(zh)
*
|
2007-12-26 |
2017-11-24 |
生物测试股份公司 |
用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
|
|
WO2009080831A1
(fr)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
|
|
CN101977934B
(zh)
|
2008-01-18 |
2014-09-17 |
健泰科生物技术公司 |
用于靶向k63连接的多聚遍在蛋白的方法和组合物
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
WO2009114560A2
(fr)
|
2008-03-10 |
2009-09-17 |
Spaltudaq Corporation |
Compositions et procédés pour le diagnostic et le traitement d’une infection à cytomégalovirus
|
|
HUE035184T2
(en)
|
2008-03-18 |
2018-05-02 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
|
HUE034763T2
(en)
|
2008-04-30 |
2018-02-28 |
Immunogen Inc |
Crosslinkers and their use
|
|
WO2009140684A2
(fr)
*
|
2008-05-16 |
2009-11-19 |
Genentech, Inc. |
Utilisation de biomarqueurs pour évaluer le traitement de troubles inflammatoires gastro-intestinaux avec des antagonistes de l'intégrine bêta7
|
|
CN102099373A
(zh)
|
2008-05-22 |
2011-06-15 |
百时美施贵宝公司 |
基于纤连蛋白的多价支架结构域蛋白
|
|
EP2318832B1
(fr)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Matrices de glycane sur des lames de verre revêtues d' aluminium de type ptfe et procédés associés
|
|
CN102282172B
(zh)
|
2008-09-07 |
2014-02-19 |
台湾醣联生技医药股份有限公司 |
抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
|
|
AU2009298569A1
(en)
|
2008-10-01 |
2010-04-08 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
|
WO2010080528A1
(fr)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Polythérapie contre le virus de l'hépatite c
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
EP3702371B1
(fr)
|
2009-03-25 |
2022-11-02 |
Genentech, Inc. |
Anticorps anti-fgfr3 et procédés d'utilisation associés
|
|
KR20120057565A
(ko)
|
2009-04-01 |
2012-06-05 |
제넨테크, 인크. |
항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
WO2010124163A2
(fr)
*
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Anticorps neutralisant le facteur de croissance des granulocytes et des macrophages (gm-csf)
|
|
US8481694B2
(en)
|
2009-04-29 |
2013-07-09 |
Bio-Rad Laboratories, Inc. |
Purification of immunoconjugates
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
MX2011012794A
(es)
|
2009-06-03 |
2012-05-08 |
Immunogen Inc |
Metodos de conjugacion.
|
|
EP2437785B1
(fr)
|
2009-06-04 |
2015-02-25 |
Novartis AG |
Procédés d'identification de sites pour la conjugaison d'igg
|
|
WO2011005481A1
(fr)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Régions fc de synthèse pour une conjugaison spécifique à un site
|
|
WO2011014750A1
(fr)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition de métastase tumorale utilisant des antagonistes de bv8 ou de g-csf
|
|
EP2473522B1
(fr)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened et ses méthodes d'utilisation
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011034605A2
(fr)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
|
US8759491B2
(en)
*
|
2009-10-19 |
2014-06-24 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック， インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
|
CA2778442A1
(fr)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Procedes et compositions pour moduler l'activation d'hepsine d'une proteine de stimulation de macrophage
|
|
WO2011056497A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
|
|
WO2011056494A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
|
|
WO2011056502A1
(fr)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
|
|
CN105274170A
(zh)
|
2009-11-05 |
2016-01-27 |
弗·哈夫曼-拉罗切有限公司 |
分泌异源多肽的方法和组合物
|
|
TWI537383B
(zh)
|
2009-11-30 |
2016-06-11 |
建南德克公司 |
診斷及治療腫瘤之組合物及方法
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
|
EP2509626B1
(fr)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anticorps anti-vegf-c et leurs procédés d'utilisation
|
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック， インコーポレイテッド |
抗Ｂｖ８抗体およびその使用
|
|
WO2011082187A1
(fr)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Procédés de modulation d'une réponse biologique à médiation par pdgf-aa
|
|
WO2011100403A1
(fr)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Anticorps anti-cd20 et utilisations de ceux-ci
|
|
CA2787657A1
(fr)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
|
TWI672318B
(zh)
|
2010-02-24 |
2019-09-21 |
美商免疫遺傳股份有限公司 |
葉酸受體１抗體類和免疫共軛物類及彼等之用途
|
|
SMT201900549T1
(it)
|
2010-03-12 |
2019-11-13 |
Debiopharm Int Sa |
Molecole leganti il cd37 e loro immunoconiugati
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
US9637557B2
(en)
|
2010-04-23 |
2017-05-02 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CN102958941A
(zh)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
MX336540B
(es)
|
2010-06-08 |
2016-01-22 |
Genentech Inc |
Conjugados y anticuerpos manipulados geneticamente con cisteina.
|
|
EP3029066B1
(fr)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Anticorps à points isoélectriques modifiés
|
|
WO2012019024A2
(fr)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Molécules se liant à her3 et leurs immunoconjugués
|
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
EP4549461A3
(fr)
|
2010-08-31 |
2025-08-06 |
Theraclone Sciences, Inc. |
Anticorps neutralisant le virus de l'immunodéficience humaine (vih)
|
|
RU2013115927A
(ru)
|
2010-09-10 |
2014-10-20 |
Апексиджен, Инк. |
АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
MX347954B
(es)
|
2010-09-29 |
2017-05-19 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
|
|
WO2012045085A1
(fr)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anticorps anti-ror1
|
|
EP2625197B1
(fr)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened et ses procédés d'utilisation
|
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
|
US8790649B2
(en)
|
2010-10-29 |
2014-07-29 |
Immunogen, Inc. |
EGFR-binding molecules and immunoconjugates thereof
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2012092539A2
(fr)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Anticorps contre dll4 et leurs utilisations
|
|
CN103649117B
(zh)
|
2011-02-04 |
2016-09-14 |
霍夫曼-拉罗奇有限公司 |
Fc变体及其生成方法
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
CA2827301A1
(fr)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions et methodes de therapie et de diagnostic de la grippe
|
|
AU2012223449A1
(en)
|
2011-03-03 |
2013-05-02 |
Apexigen, Inc. |
Anti-IL-6 receptor antibodies and methods of use
|
|
US20120315277A1
(en)
|
2011-03-15 |
2012-12-13 |
Theraclone Sciences, Inc. |
Compositions and Methods for the Therapy and Diagnosis of Influenza
|
|
TWI719112B
(zh)
|
2011-03-16 |
2021-02-21 |
賽諾菲公司 |
雙重ｖ區類抗體蛋白質之用途
|
|
ME03353B
(fr)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
|
|
WO2012135517A2
(fr)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
|
|
WO2012149356A2
(fr)
|
2011-04-29 |
2012-11-01 |
Apexigen, Inc. |
Anticorps anti-cd40 et leurs procédés d'utilisation
|
|
CA2835203A1
(fr)
|
2011-05-09 |
2012-11-15 |
University Of Virginia Patent Foundation |
Compositions et procedes pour le traitement du cancer
|
|
SG194176A1
(en)
|
2011-05-27 |
2013-12-30 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
EP3228325A1
(fr)
|
2011-06-10 |
2017-10-11 |
Mersana Therapeutics, Inc. |
Conjugués protéine-polymère-médicament
|
|
SG10201605041VA
(en)
|
2011-06-21 |
2016-08-30 |
Immunogen Inc |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
|
EP2736928B1
(fr)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Proteines "sur"-liantes dirigees contre erbb3
|
|
WO2013022855A1
(fr)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Anticorps avec points isoélectriques modifiés et immunofiltration
|
|
WO2013025944A1
(fr)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition de l'angiogenèse dans les tumeurs réfractaires
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
CN104136461B
(zh)
|
2011-09-22 |
2021-06-08 |
安姆根有限公司 |
Cd27l抗原结合蛋白
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2851534C
(fr)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
Procede de purification d'anticorps
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2850034A1
(fr)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Associations therapeutiques et methodes de traitement du melanome
|
|
CA2854153A1
(fr)
|
2011-11-02 |
2013-05-10 |
Apexigen, Inc. |
Anticorps anti-kdr et procedes d'utilisation
|
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
|
CN104302324A
(zh)
|
2011-12-08 |
2015-01-21 |
生物测试股份公司 |
靶向cd138的免疫偶联物的用途
|
|
EP2793940B1
(fr)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Protéines substitutives de liaison
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
WO2013106489A1
(fr)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Anticorps humanisés à cdr3 ultralongues
|
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
|
WO2013130093A1
(fr)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
|
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
JP6242865B2
(ja)
|
2012-05-01 |
2017-12-06 |
ジェネンテック， インコーポレイテッド |
抗ｐｍｅｌ１７抗体および免疫複合体
|
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
WO2014055877A1
(fr)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Utilisation d'une membrane de pvdf pour purifier des conjugués d'agent de liaison cellulaire-agent cytotoxique
|
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
SI2922875T1
(sl)
|
2012-11-20 |
2017-06-30 |
Sanofi |
Protitelesa anti-CEACAM5 in njihove uporabe
|
|
CA2891280C
(fr)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
EP2931316B1
(fr)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugués hydroxy-polymère-médicament-protéine
|
|
CN105007941B
(zh)
|
2012-12-27 |
2019-01-25 |
赛诺菲 |
抗-lamp1抗体和抗体药物偶联物及其用途
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EA201591750A1
(ru)
|
2013-03-14 |
2016-05-31 |
Дженентек, Инк. |
Антитела против b7-h4 и иммуноконъюгаты
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
EP3421495A3
(fr)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation de cellules t avec des anticorps bispécifiques et des fusions fc
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
JP2016520586A
(ja)
|
2013-05-08 |
2016-07-14 |
ザイムワークス，インコーポレイテッド |
二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
|
|
CN110511279B
(zh)
|
2013-05-30 |
2024-03-29 |
基尼克萨制药有限公司 |
制瘤素m受体抗原结合蛋白
|
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
|
WO2014210564A1
(fr)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Conjugués de glycane et leur utilisation
|
|
EP3022224A2
(fr)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Anticorps à régions de détermination de complémentarité ultralongues
|
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
|
EP3738612A1
(fr)
|
2013-07-31 |
2020-11-18 |
Biontech AG |
Diagnostic et traitement du cancer impliquant des cellules souches cancéreuses
|
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
|
CA2923579C
(fr)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Activation des cellules humaines inkt a l'aide de glycolipides ayant des groupes glycolsyles modifies
|
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
|
MY174670A
(en)
|
2013-10-08 |
2020-05-06 |
Immunogen Inc |
Anti-folr1 immunoconjugate dosing regimens
|
|
CA2926586C
(fr)
|
2013-10-11 |
2020-04-07 |
Mersana Therapeutics, Inc. |
Echafaudage polymere fonde sur le phf pour la liberation de medicaments a cible definie
|
|
KR102572149B1
(ko)
|
2013-10-11 |
2023-08-30 |
아사나 바이오사이언시스 엘엘씨 |
단백질-폴리머-약물 접합체
|
|
HRP20210410T1
(hr)
|
2013-10-11 |
2021-04-30 |
Oxford Bio Therapeutics Limited |
Konjugirana antitijela prema ly75 za liječenje raka
|
|
CA2925393C
(fr)
|
2013-10-11 |
2023-03-07 |
Dimiter Dimitrov |
Anticorps tem8 et leur utilisation
|
|
WO2015069922A2
(fr)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-alk, conjugues, et recepteurs antigeniques chimeriques, et leur utilisation
|
|
KR20160083949A
(ko)
|
2013-11-13 |
2016-07-12 |
자임워크스 인코포레이티드 |
Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
|
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
|
JP6895254B2
(ja)
|
2013-12-16 |
2021-06-30 |
ジェネンテック， インコーポレイテッド |
ペプチド模倣化合物及びその抗体−薬物コンジュゲート
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
|
CA2937539A1
(fr)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened et methodes d'utilisation de celui-ci
|
|
CN106414465B
(zh)
|
2014-02-28 |
2021-11-16 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
ES2819863T3
(es)
|
2014-04-11 |
2021-04-19 |
Medimmune Llc |
Anticuerpos contra HER2 biespecíficos
|
|
HUE063273T2
(hu)
|
2014-05-06 |
2024-01-28 |
Hoffmann La Roche |
Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
|
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
EP3904388A1
(fr)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase issue de bacteroïdes et ses procédés d'utilisation
|
|
US20150344585A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
CN106661099A
(zh)
|
2014-05-27 |
2017-05-10 |
中央研究院 |
抗her2醣抗体及其用途
|
|
EP3154582A4
(fr)
|
2014-05-28 |
2018-01-10 |
Academia Sinica |
Glycoanticorps anti-thf-alpha et leurs utilisations
|
|
CA2956178A1
(fr)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Elimination rapide de complexes antigeniques a l'aide de nouveaux anticorps
|
|
EA201790334A1
(ru)
|
2014-08-12 |
2017-06-30 |
Новартис Аг |
Конъюгаты анти-cdh6 антитела с лекарственным средством
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
SG11201701328XA
(en)
|
2014-09-02 |
2017-03-30 |
Immunogen Inc |
Methods for formulating antibody drug conjugate compositions
|
|
EP3191500A4
(fr)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
Activation des cellules inkt humaines par des glycolipides
|
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
SG11201701627PA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
|
AU2015314954B2
(en)
|
2014-09-12 |
2021-05-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
CA2962783A1
(fr)
|
2014-10-01 |
2016-04-07 |
Medimmune, Llc |
Methode de conjugaison d'un polypeptide
|
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
|
RU2711930C2
(ru)
|
2014-11-19 |
2020-01-23 |
Иммуноджен, Инк. |
Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
CA2967426A1
(fr)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral
|
|
WO2016087416A1
(fr)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Anticorps multispécifiques
|
|
ES2986970T3
(es)
|
2014-12-04 |
2024-11-13 |
Celgene Corp |
Conjugados de biomoléculas
|
|
EP3237449A2
(fr)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Anticorps trispécifiques
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
CA2972072A1
(fr)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Nouveaux composes conjugues de glycane et leurs methodes d'utilisation
|
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2016141387A1
(fr)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
|
|
CN107614020A
(zh)
|
2015-03-18 |
2018-01-19 |
免疫生化公司 |
靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
|
|
WO2016165762A1
(fr)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
|
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
|
CN108603170A
(zh)
|
2015-06-12 |
2018-09-28 |
莱蒂恩技术公司 |
用工程改造的t细胞治疗癌症的方法
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
KR102700777B1
(ko)
|
2015-09-17 |
2024-08-29 |
이뮤노젠 아이엔씨 |
항-folr1 면역접합체를 포함하는 치료제 조합
|
|
EP4477269A3
(fr)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Anticorps monoclonaux spécifiques du récepteur de facteur de croissance des fibroblastes 4 (fgfr4) et leurs procédés d'utilisation
|
|
WO2017062820A1
(fr)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Récepteurs antigéniques chimériques et leurs procédés d'utilisation
|
|
WO2017066714A1
(fr)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Conjugués d'anticorps anti-vsig1 et de médicaments
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
WO2017132298A1
(fr)
|
2016-01-27 |
2017-08-03 |
Medimmune, Llc |
Procédé de préparation d'anticorps ayant un profil de glycosylation défini
|
|
EP3411396A1
(fr)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened et méthodes d'utilisation dudit mutant
|
|
AU2017213858A1
(en)
|
2016-02-05 |
2018-08-16 |
Immunogen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
KR20180114210A
(ko)
|
2016-03-08 |
2018-10-17 |
아카데미아 시니카 |
N-글리칸의 모듈 합성 방법 및 그의 어레이
|
|
WO2017161206A1
(fr)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
|
|
AU2017250191A1
(en)
|
2016-04-13 |
2018-11-08 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
KR102606938B1
(ko)
|
2016-04-15 |
2023-11-29 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
|
WO2017196847A1
(fr)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
|
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
|
|
EP3455261B1
(fr)
|
2016-05-13 |
2022-08-03 |
BioAtla, Inc. |
Anticorps anti-ror2, fragments d'anticorps, leurs immunoconjugués et utilisations correspondantes
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
WO2017214182A1
(fr)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
|
|
CA3026151A1
(fr)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Anticorps inhibiteurs de points de controle bispecifiques
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
CA3031559A1
(fr)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux ciblant le glypican-2 (gpc2) et leur utilisation
|
|
EP3494139B1
(fr)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation
|
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
WO2018091724A1
(fr)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anticorps anti-gp73 et immunoconjugués
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
EP3882265B1
(fr)
|
2017-01-09 |
2022-11-02 |
Lentigen Technology, Inc. |
Compositions et procédés pour le traitement du cancer avec immunothérapie anti-mésothéline
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
|
WO2018175988A1
(fr)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions et procédés pour le traitement du cancer avec immunothérapie anti-cd33
|
|
WO2018185618A1
(fr)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
|
|
WO2018213064A1
(fr)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonal humain ciblant tnfer2 en immunothérapie anticancéreuse
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
CA3066754A1
(fr)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Procedes de production de matrices polymeres transportant des medicaments, et conjugues proteine-polymere-medicament
|
|
WO2019006280A1
(fr)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019005208A1
(fr)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse
|
|
WO2019028051A1
(fr)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions et méthodes de traitement du cancer par immunothérapie anti-cd19/cd20
|
|
CN107446050A
(zh)
|
2017-08-11 |
2017-12-08 |
百奥泰生物科技(广州)有限公司 |
Trop2阳性疾病治疗的化合物及方法
|
|
US11524082B2
(en)
|
2017-08-22 |
2022-12-13 |
Purdue Research Foundation |
FBSA-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
|
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
|
|
AU2018354189A1
(en)
|
2017-10-24 |
2020-04-23 |
Crispr Therapeutics Ag |
Compositions and methods for the depletion of CD117+ cells
|
|
CN117756946A
(zh)
|
2017-11-03 |
2024-03-26 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
SG11202004294XA
(en)
|
2017-11-29 |
2020-06-29 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cd5+ cells
|
|
WO2019118937A1
(fr)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
|
EP3728302A1
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Protéines de fusion il-2 fc modifiées
|
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
|
EP3768714A1
(fr)
|
2018-03-23 |
2021-01-27 |
Seagen Inc. |
Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide
|
|
EP3773911A2
(fr)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
ES2975330T3
(es)
|
2018-05-04 |
2024-07-04 |
Tagworks Pharmaceuticals B V |
Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
|
|
US20210299286A1
(en)
|
2018-05-04 |
2021-09-30 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
KR20210014684A
(ko)
|
2018-05-30 |
2021-02-09 |
데비오팜 인터네셔날 에스 에이 |
항-cd37 면역접합체 투약 용법
|
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
|
US11530274B2
(en)
|
2018-07-02 |
2022-12-20 |
Amgen Inc. |
Anti-STEAP1 antigen-binding protein
|
|
WO2020014482A1
(fr)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonal spécifique pour cd22 à maturation par affinité et utilisations associées
|
|
JP2021532116A
(ja)
|
2018-07-23 |
2021-11-25 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
|
|
AU2019317565A1
(en)
|
2018-08-08 |
2021-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
JP7546553B2
(ja)
|
2018-09-20 |
2024-09-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
|
|
CN113286607B
(zh)
|
2018-09-26 |
2024-07-12 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
|
AU2019387377A1
(en)
|
2018-11-30 |
2021-06-17 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
|
EP3883608A1
(fr)
|
2019-01-08 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anticorps à domaine unique hétérospécifiques ciblant la mésothéline pour le traitement de tumeurs solides
|
|
EP3883971A1
(fr)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anticorps monoclonaux à haute affinité ciblant le glypicane-1 et procédés d'utilisation
|
|
MX2021009514A
(es)
|
2019-02-07 |
2021-11-04 |
Sanofi Sa |
Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
|
|
EP3693023A1
(fr)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
US11969443B2
(en)
|
2019-03-06 |
2024-04-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
CN114364801B
(zh)
|
2019-05-30 |
2024-04-19 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
IL289093B2
(en)
|
2019-06-17 |
2025-02-01 |
Tagworks Pharmaceuticals B V |
Compounds for a fast and efficient "click release" reaction
|
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
JPWO2021010326A1
(fr)
|
2019-07-12 |
2021-01-21 |
|
|
|
WO2021076196A1
(fr)
|
2019-10-18 |
2021-04-22 |
Genentech, Inc. |
Procédés d'utilisation d'immunoconjugués anti-cd79b pour traiter un lymphome diffus à grandes cellules b
|
|
US12552865B2
(en)
|
2019-10-22 |
2026-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors
|
|
CN120718040A
(zh)
|
2019-11-05 |
2025-09-30 |
佐治亚大学研究基金会股份有限公司 |
功能改性的美登木素生物碱及其组合物和使用方法
|
|
CA3161573A1
(fr)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Conjugues anticorps-medicament specifiques a cd276 et leurs utilisations
|
|
EP4139359A1
(fr)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Procédés d'utilisation d'immunoconjugués anti-cd79b
|
|
KR20230005257A
(ko)
|
2020-04-24 |
2023-01-09 |
사노피 |
항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물
|
|
WO2021214223A1
(fr)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfox
|
|
MX2022013406A
(es)
|
2020-04-24 |
2022-11-14 |
Sanofi Sa |
Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
|
|
MX2022013404A
(es)
|
2020-04-24 |
2022-11-14 |
Sanofi Sa |
Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CN116801898A
(zh)
|
2020-11-05 |
2023-09-22 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
EP4240415A1
(fr)
|
2020-11-08 |
2023-09-13 |
Seagen Inc. |
Polythérapie à base d'un conjugué anticorps-médicament avec un nhibiteur de cellules immunitaires
|
|
IL302731A
(en)
|
2020-11-10 |
2023-07-01 |
Sanofi Sa |
Formulation of an antibody-drug conjugate for CEACAM5
|
|
CA3212665A1
(fr)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Anticorps heterodimeriques se liant a cd3 et a cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
CA3215049A1
(fr)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation
|
|
WO2022226317A1
(fr)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
CA3218170A1
(fr)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methodes d'utilisation d'immunoconjugues anti-cd79b pour traiter un lymphome diffus a grandes cellules b
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
|
CA3216228A1
(fr)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps a domaine unique heterospecifiques ciblant pd-l1 pour le traitement de tumeurs solides
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN118339280A
(zh)
|
2021-09-06 |
2024-07-12 |
维拉克萨生物技术有限责任公司 |
用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
|
|
EP4412713A1
(fr)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Polythérapies pour le traitement du cancer
|
|
WO2022078524A2
(fr)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugaison spécifique d'un anticorps
|
|
TW202333797A
(zh)
|
2021-11-05 |
2023-09-01 |
法商賽諾菲公司 |
含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
|
|
US20250073346A1
(en)
|
2021-11-18 |
2025-03-06 |
Oxford Bio Therapeutics Ltd |
Pharmaceutical combinations
|
|
JP2024540536A
(ja)
|
2021-11-19 |
2024-10-31 |
アーディアジェン コーポレーション |
Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法
|
|
KR20240105469A
(ko)
|
2021-11-25 |
2024-07-05 |
베락사 바이오테크 게엠베하 |
유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
|
|
DK4186529T3
(da)
|
2021-11-25 |
2025-08-25 |
Veraxa Biotech Gmbh |
Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
|
|
CA3241254A1
(fr)
|
2021-12-02 |
2023-06-08 |
Sanofi |
Polytherapie a base de ceacam5 adc anti-pd-1/pd-l1
|
|
KR20240112348A
(ko)
|
2021-12-02 |
2024-07-18 |
사노피 |
암 치료법에서 환자 선택을 위한 cea 검정
|
|
WO2023104941A1
(fr)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Charges utiles hydrophiles fonctionnalisées à la tétrazine destinées à la préparation de conjugués de ciblage
|
|
JP2024546948A
(ja)
|
2021-12-15 |
2024-12-26 |
ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド |
コンジュゲート、それらの組成物、及びそれらの関連する方法
|
|
DK4314031T3
(da)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
Maskeret il12-protein
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
CA3261603A1
(fr)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Conjugués anticorps-médicament
|
|
AU2023314413A1
(en)
|
2022-07-28 |
2025-02-13 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
|
WO2024080872A1
(fr)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Bicyclononènes contraints
|
|
WO2024153789A1
(fr)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Composition de biopolymère stabilisée, sa fabrication et son utilisation
|
|
EP4673181A1
(fr)
|
2023-03-01 |
2026-01-07 |
Sanofi |
Utilisation d'immunoconjugués anti-ceacam5 pour le traitement de cancers neuroendocriniens exprimant ceacam5
|
|
EP4427763A1
(fr)
|
2023-03-06 |
2024-09-11 |
Sanofi |
Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
|
|
KR20250169530A
(ko)
|
2023-03-10 |
2025-12-03 |
태그웍스 파마슈티컬스 비.브이. |
개선된 t-링커를 갖는 트랜스-사이클로옥텐
|
|
CN120917154A
(zh)
|
2023-03-23 |
2025-11-07 |
赛诺菲 |
用于癌症疗法中的患者选择的CEACAM5 mRNA测定
|
|
EP4698225A1
(fr)
|
2023-04-21 |
2026-02-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Chimères ciblant la cytotoxicité pour conjugués anticorps-médicament et anticorps bispécifiques
|
|
CN121443320A
(zh)
|
2023-06-05 |
2026-01-30 |
赛诺菲 |
含有抗ceacam5抗体-药物缀合物、抗pd1/pd-l1抗体和抗ctla4抗体的抗肿瘤组合
|
|
WO2024254455A1
(fr)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Signatures de macrophages pour méthodes diagnostiques et thérapeutiques pour un lymphome
|
|
WO2025014896A1
(fr)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps 40h3 humanisé
|
|
WO2025019228A1
(fr)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux entièrement humains et récepteurs antigéniques chimériques dirigés contre cd276 pour le traitement de tumeurs solides
|
|
CN121646574A
(zh)
|
2023-07-27 |
2026-03-10 |
维拉克萨生物技术有限责任公司 |
亲水性反式环辛烯(hyTCO)化合物、含有该化合物的构建体和缀合物
|
|
WO2025056807A1
(fr)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Compositions biopolymère stabilisées, leur fabrication et utilisation
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025094146A1
(fr)
|
2023-11-02 |
2025-05-08 |
Immunogen Switzerland Gmbh |
Vasoconstricteurs pour réduire la toxicité oculaire de conjugués anticorps-maytansinoïde
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
WO2025149667A1
(fr)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Conjugués anticorps-médicament et leurs utilisations
|
|
WO2025169012A1
(fr)
|
2024-02-06 |
2025-08-14 |
Sanofi |
Méthodes de traitement de cancers exprimant ceacam5
|
|
WO2025171238A1
(fr)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps monoclonaux qui se lient à la région juxtamembranaire de la mésothéline et leurs utilisations
|
|
WO2025174248A1
(fr)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctènes à libération avec "fonction ou"
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20260000765A1
(en)
|
2024-06-27 |
2026-01-01 |
Lentigen Technology, Inc. |
CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
|
|
WO2026039642A1
(fr)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Conjugués d'anticorps anti-mésothéline et leurs procédés d'utilisation
|
|
WO2026043376A1
(fr)
|
2024-08-22 |
2026-02-26 |
Tagworks Pharmaceuticals B.V. |
Formulations de trans-cyclooctène
|